Anzeige
Mehr »
Login
Mittwoch, 17.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PRLN | ISIN: US85205L1070 | Ticker-Symbol:
NASDAQ
17.04.24
20:38 Uhr
44,390 US-Dollar
+0,980
+2,26 %
1-Jahres-Chart
SPRINGWORKS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SPRINGWORKS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SPRINGWORKS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.03.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN97STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced...
► Artikel lesen
29.02.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors359Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements...
► Artikel lesen
27.02.SpringWorks Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
27.02.SpringWorks Therapeutics GAAP EPS of -$5.15 misses by $0.23, revenue of $5.45M1
27.02.SpringWorks Therapeutics, Inc. - 10-K, Annual Report-
27.02.SpringWorks Therapeutics, Inc. - 8-K, Current Report1
27.02.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates172- Reported OGSIVEO (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 - - Submitted Marketing Authorization Application...
► Artikel lesen
22.02.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Present at Upcoming Investor Conferences1
16.02.SpringWorks Therapeutics jumps amid takeover speculation2
06.02.Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks6
02.02.SpringWorks Therapeutics, Inc. - 8-K, Current Report1
31.01.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference1
25.01.SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why3
19.01.SpringWorks Therapeutics' Options Frenzy: What You Need to Know3
08.01.SpringWorks reports 2023 achievements and 2024 goals1
08.01.SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference1
21.12.23SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference2
08.12.23SpringWorks Therapeutics announces closing of upsized public offering of common stock3
08.12.23SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares1
06.12.23SpringWorks Therapeutics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1